Acura Pharmaceuticals Inc ACUR

$0.00 0.00 (—)

Valuation

Market cap
7,000
Revenue TTM
$1,560,000
Net income TTM
$-880,000
PE ratio
0.00
Forward PE
—
Profit margin
-56.41%
Debt to equity
0.00

Trading

Volume
100
Avg volume
3,094
Day's range
$0.00 – $0.00
Shares out
66,649,000
Stochastic %K
50%
Beta
-12.37
Analysts
Strong Buy
Price target
$6.00

Price

Company profile

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are u...

Show more

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
847 705 7709
Website
https://www.acurapharm.com
Address
616 N. North Court, Suite 120, Palatine, United States

Latest news

No headlines yet.